GIC-Reliance Retail deal: Singapore investment company to pump Rs 5,512.5 crore for 1.22% of RIL unit

Deals in recent weeks underline growing interest from global investors in the retail division of Mukesh Ambani-controlled Reliance Industries

Singapore investment company GIC will invest Rs 5,512.5 crore in the retail unit of Reliance Industries (RIL), joining the rush of global investors buying stakes in the Indian company.

This latest investment — the sixth in recent weeks — in exchange for 1.22 percent stake values Reliance Retail Ventures (RRVL) at a pre-money equity value of Rs 4.285 lakh crore, Mukesh Ambani-controlled RIL said in a late-night statement on October 2.

Mukesh Ambani, Chairman and Managing Director of Reliance Industries, said, “GIC’s global network and track record of long-term partnerships will be invaluable to the transformation story of Indian retail. This investment is a strong endorsement of our strategy and India’s potential.”

Lim Chow Kiat, CEO, GIC, said, “We believe Reliance Retail will continue to use its extensive supply chain and store networks, as well as strong logistics and data infrastructure, to add value to its customers and shareholders.”

Reliance Retail has so far attracted investments worth Rs 30,360 crore in exchange for a combined 6.87 percent stake.

On October 1, Abu Dhabi state fund Mubadala Investment Co said it will invest Rs 6,247.5 crore to secure 1.4 percent in the retail unit of Reliance Industries (RIL).

This investment — with Silver Lake's co-investors and General Atlantic, the sixth in three weeks — too valued Reliance Retail at a pre-money equity value of Rs 4.285 lakh crore.

Reliance Retail operates India's largest, fastest growing and most profitable retail business serving close to 640 million footfalls across its nearly 12,000 stores nationwide.

GIC is a leading global investment firm established in 1981 to manage Singapore’s foreign reserves, said the RIL statement. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate and infrastructure, it said.

GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, it employs over 1,700 people across 10 offices in key financial cities worldwide.

The transaction is subject to regulatory and other customary approvals.

Morgan Stanley acted as financial advisor to Reliance Retail and Cyril Amarchand Mangaldas and Davis Polk & Wardwell acted as legal counsels.

Source - Moneycontrol.com

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

SD Solutions

Search This Blog